About Biquelle XL

Welcome to

Biquelle XL is a prolonged-release tablet of quetiapine indicated for the:1

  • Treatment of schizophrenia;

  • Treatment of moderate to severe manic and major depressive episodes in bipolar disorder;

  • Prevention of recurrence of manic or depressive episodes in patients with bipolar disorder who have previously responded to quetiapine;

  • Treatment of major depressive episodes in patients with Major Depressive Disorder who have had sub-optimal response to antidepressant monotherapy as an add-on treatment.

Schizophrenia and medication adherence

It is well documented that a recommended daily dosage of 600mg is effective in the acute treatment of schizophrenia, while long-term quetiapine XL is significantly more effective than placebo at preventing relapse.1-5

Adherence to medication is essential for the alleviation of symptoms, with effective management of schizophrenia still remaining a significant challenge to clinicians.2-5 Approximately 70-80% of persons with schizophrenia find treatment with first-line antipsychotic medications effective, however, an estimated 50% of those who respond well to medications are non-adherent to treatment regimen.2-5

The recommended daily dosage for treatment of schizophrenia currently necessitates taking two Quetiapine XL 300mg tablets.1,2 With the launch of Biquelle XL 600mg tablets, this reduces the number of tablets taken daily for a standard 600mg daily dosage for schizophrenia.1 Reducing the amount of tablets a patient needs to take daily, may increase their compliance and adherence to treatment, as well as improving long-term outcomes.2-5

Available as:

  • 50mg prolonged-release tablets

  • 150mg prolonged-release tablets

  • 200mg prolonged-release tablets

  • 300mg prolonged-release tablets

  • 400mg prolonged-release tablets

  • 600mg prolonged-release tablets

Biquelle XL is bioequivalent to Seroquel (quetiapine) XL tablets (AstraZeneca, London, UK).6

Biquelle XL could offer significant cost savings to your practice and clinical commissioning group (CCG).

Quetiapine 50mg, 150mg, 200mg, 300mg and 400mg prolonged-release tablets are in category C of the UK Drug Tariffs.7

However, the NHS can make up to 56% savings on the cost of category C quetiapine by prescribing Biquelle XL by brand name.7*

Quite simply a wholesale switch of quetiapine 50mg, 150mg, 200mg, 300mg and 400mg prolonged-release prescriptions to Biquelle XL could still save an average CCG £52,795 per year.8**

Biquelle XL is one of Aspire Pharma’s cost saving prolonged-release products.

In addition, Biquelle XL:

  • Full range of strengths available for Biquelle XL;

  • The only 600mg strength available7;

  • Now available in 30 tablet packs for dispensing or splitting versus 60’s1,7;

  • Available from mainline wholesalers;

  • High level of stockholdings;

  • Bioequivalent to the originator brand;6

  • Price guaranteed***

*Based on 56% saving when prescribing Biquelle XL 50, 150, 200, 300 and 400mg tablets only, versus the cost of Category C quetiapine XL on the UK Drug Tariffs. ** Potential still to save based on the market data in reference 4 for 161 CCGs switching their generic and brand originator quetiapine prolonged-release tablet prescriptions to Biquelle XL. ***No change in price subject to no material change to the products or Category C of the UK Drug Tariffs until the 2024 PPRS review.
References: 1) Biquelle XL SmPCs. 2) Peuskens J. (2011). The management of schizophrenia: focus on extended-release quetiapine fumarate. Neuropsychiatric disease and treatment, 7, 549–564. 3) Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002). Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. The Journal of Clinical Psychiatry, 63(10), 892–909. 4) Acosta, F. J., Hernández, J. L., Pereira, J., Herrera, J., & Rodríguez, C. J. (2012). Medication adherence in schizophrenia. World journal of psychiatry, 2(5), 74–82. 5) El-Mallakh, P., & Findlay, J. (2015). Strategies to improve medication adherence in patients with schizophrenia: the role of support services. Neuropsychiatric disease and treatment, 11, 1077–1090. 6) Data on file, 1010067149 v 4.0 October 2019. 7) July 2022 UK Drug Tariffs. 8) Insypher data GPPLPD Date Range: Jun20 -Aug 20 MQT*4
For further information please call: 01730 231148,
email: or visit
Adverse events should be reported. Reporting forms and information can be found at
Adverse events should also be reported to Aspire Pharma Ltd on 01730 231148

For more information about Biquelle XL, please see the abbreviated prescribing information.

Revision reference – Biquelle XL_20_27.07.2022

More products available
in this range:
Click to view their
individual websites